{"filing":{"accession_number":"0001193125-26-346894","cik":"0001574094","ticker":"RNXT","company_name":"RenovoRx, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"rnxt-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1574094/000119312526346894/rnxt-20260812.htm"},"events":[{"id":27230,"run_id":24805,"accession_number":"0001193125-26-346894","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"RenovoRx issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $909,000 (61% sequential growth, 115% year-over-year growth), gross profit of $766,000 (84% margin), net loss of $2.9 million, and raising full-year 2026 revenue guidance to $3.75M–$4.25M. This is a standard quarterly earnings release with detailed financial statements and operational metrics, clearly falling under Item 2.02 disclosure of results of operations and financial condition.","company_name":"RenovoRx, Inc.","ticker":"RNXT","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28667,"accession_number":"0001193125-26-346894","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"RenovoRx issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $909,000 (61% sequential growth, 115% year-over-year growth), gross profit of $766,000 (84% margin), net loss of $2.9 million, and raising full-year 2026 revenue guidance to $3.75M–$4.25M. This is a standard quarterly earnings release with detailed financial statements and operational metrics, clearly falling under Item 2.02 disclosure of results of operations and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:22:40.007762+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28667,"accession_number":"0001193125-26-346894","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"RenovoRx issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $909,000 (61% sequential growth, 115% year-over-year growth), gross profit of $766,000 (84% margin), net loss of $2.9 million, and raising full-year 2026 revenue guidance to $3.75M–$4.25M. This is a standard quarterly earnings release with detailed financial statements and operational metrics, clearly falling under Item 2.02 disclosure of results of operations and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:22:40.007762+00:00","company_name":"RenovoRx, Inc.","ticker":"RNXT","filing_date":"2026-08-12"}]}